From surgical possibility to sustained survival

Organ transplantation developed through several overlapping problems: connecting a donor organ to a recipient’s circulation, understanding rejection, protecting donors and sustaining recipients after surgery. Its history therefore cannot be reduced to a single operation. A technically completed transplant, temporary organ function and prolonged patient survival describe different achievements. Historical claims about a “first” need to specify which outcome they mean.

The field also depended on work beyond the operating theatre. Laboratory researchers, nurses, physicians, donors and families helped make transplantation possible. Institutional accounts and prize lectures preserve valuable evidence, but their emphasis on celebrated pioneers can obscure this collective work. Read alongside the broader history of surgery, transplantation illustrates how an experimental intervention became an enduring responsibility for teams and patients.

Recognizing the immune barrier

During the Second World War, Peter Medawar investigated why skin transferred between people generally failed to become a permanent graft. This research helped establish that graft survival involved the recipient’s immune response, rather than surgical technique alone. Subsequent experimental work showed that tolerance to transplanted tissue could be acquired under particular conditions. Medawar and Frank Macfarlane Burnet shared the 1960 Nobel Prize for the discovery of acquired immunological tolerance.

These findings changed the questions researchers could ask. Instead of treating rejection as an inexplicable failure, they could investigate its biological mechanisms and possible modification. Experimental tolerance nevertheless did not mean that ordinary human organ transplantation had become straightforward. A laboratory demonstration and a dependable treatment for unrelated patients remained distinct achievements. Medawar’s Nobel biography documents the experimental background.

Kidney transplantation and the problem of rejection

The lasting kidney transplant success of 1954, involving the identical Herrick twins and Joseph Murray’s team in Boston, demonstrated that a transplanted kidney could sustain a recipient. The twins’ genetic similarity made this an exceptional case: it did not establish that the same result could routinely be achieved between unrelated people.

Drug treatment subsequently widened the possibilities. Murray’s retrospective account describes early clinical use of azathioprine and the addition of corticosteroids to transplantation practice. These advances came with serious failures. Some early recipients died from drug toxicity or infection even when the transplanted kidney initially functioned. The historical lesson is that suppressing rejection created another set of hazards; success required attention to the whole patient, not simply the graft.

Murray’s lecture is both evidence about these developments and a participant’s interpretation of them. Its descriptions of experimental treatment must not be read as present-day prescribing guidance. Murray’s Nobel lecture recounts these achievements and losses.

Heart transplantation and public attention

On 3 December 1967, Christiaan Barnard’s team at Groote Schuur Hospital in Cape Town transplanted Denise Darvall’s heart into Louis Washkansky. This human heart transplant drew international attention. Washkansky survived only eighteen days and died from pneumonia, making the distinction between an operative breakthrough and durable recovery especially important. The University of Cape Town’s anniversary account records this outcome.

The university’s institutional history also describes the contribution of nursing, anaesthesia, laboratory services, cardiology and technical staff. Such evidence challenges a history organized entirely around an individual surgeon. Donor families were equally indispensable: transplantation depended on decisions made amid bereavement as well as on surgical expertise. The operation’s significance includes these human relationships and the ethical uncertainty surrounding an unprecedented intervention. UCT’s account of the operation emphasizes the supporting disciplines.

Consent, allocation and historical legacy

Transplantation made the source and distribution of treatment unusually visible: an organ available to one recipient could not simultaneously benefit another. Its history consequently belongs within the history of medical ethics, including questions about consent, donor protection, commercial pressure and fair access.

The World Health Organization’s guiding principles, endorsed by the World Health Assembly in 2010, provide an identifiable historical expression of these concerns. They address consent, protection of living donors, independence in determining death, opposition to payment for organs, and allocation according to clinical criteria and ethical norms rather than financial considerations. These principles document a governance framework; they do not demonstrate that every transplantation system followed it. The Transplantation Society reproduces the WHO principles.

Taken together, these sources suggest a broader historical legacy: transplantation changed medicine’s expectations of what could be treated while making technical achievement inseparable from continuing care and public trust. A balanced account must preserve both the lives extended and the experimental losses, without treating early methods as recommendations for patients today.

Sources and further reading